The 21st Century Cures Act, as well as FDA guidelines, are putting a spotlight on patient centricity—from drug development to patient care. In a recent report, ICON surveyed top payers in the US to determine how PROs impact decisions across this spectrum, including predictions regarding future coverage decisions, the use of QALYs (quality adjusted life years), and the impact of ICER.
“[S]ponsors are increasingly collecting patient reported outcomes (PROs) data as endpoints in pivotal trials and using them to support label claims. This trend thus begs the question: will US payers give more consideration to PRO data when making their coverage and formulary decisions?” Read more here.
(Source: ICON, 2021)